Department of Otorhinolaryngology, Skull Base Surgery, Pellegrin University Hospital, Centre F-X Michelet, place A. Raba-Léon F-33076, Bordeaux Cedex, France.
Head Neck. 2011 Jan;33(1):82-6. doi: 10.1002/hed.21402.
The purpose of our study was to assess the long-term results in the management of patients with esthesioneuroblastoma.
A total of 28 patients were retrospectively reviewed to analyze their clinical features, treatment outcomes, pattern of failures, and course of the disease.
The patients were classified as 2 patients with T1, 10 patients with T2, 10 patients with T3, and 6 patients with T4; the results of all were included in this study. Twenty-six patients underwent surgery and 23 had postoperative radiotherapy over the tumor bed, only 9 had radiotherapy over the nodes. The average follow-up was 99.11 months. Fifteen-year and 20-year disease-specific and disease-free survival rates were 88.6% to 66.4% and 59.6% to 29.8%, respectively. Six patients had recurrences and 60% of them occurred more than 10 years after treatment. In the first decade, nodal recurrences appeared earlier than local ones when patients with N0 did not undergo neck irradiation.
Surgery on patients with T presentations and adjuvant radiotherapy on T and N0 neck presentations seem to be essential to treat esthesioneuroblastoma. A follow-up for a minimum of 20 years is necessary to ensure complete cure.
我们研究的目的是评估嗅神经母细胞瘤患者的长期治疗结果。
回顾性分析 28 例患者的临床特征、治疗结果、失败模式和疾病过程。
患者被分为 T1 期 2 例、T2 期 10 例、T3 期 10 例和 T4 期 6 例；所有患者均包括在本研究中。26 例患者接受了手术，23 例患者在肿瘤床部位进行了术后放疗，仅有 9 例患者对淋巴结进行了放疗。平均随访时间为 99.11 个月。15 年和 20 年的疾病特异性生存率和无病生存率分别为 88.6%至 66.4%和 59.6%至 29.8%。6 例患者复发，其中 60%发生在治疗后 10 年以上。在第一个十年中，对于未接受颈部照射的 N0 患者，颈部淋巴结复发早于局部复发。
对于 T 期患者进行手术和 T 和 N0 颈部患者进行辅助放疗似乎是治疗嗅神经母细胞瘤的必要手段。需要至少 20 年的随访以确保完全治愈。
